1391 related articles for article (PubMed ID: 20543764)
1. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
3. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
4. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.
Chen E; Kaiser RS; Vander JF
Retina; 2007; 27(4):445-50. PubMed ID: 17420696
[TBL] [Abstract][Full Text] [Related]
8. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
9. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.
Chan CK; Abraham P; Meyer CH; Kokame GT; Kaiser PK; Rauser ME; Gross JG; Nuthi AS; Lin SG; Daher NS
Retina; 2010 Feb; 30(2):203-11. PubMed ID: 19952998
[TBL] [Abstract][Full Text] [Related]
10. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
12. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.
Baba T; Kitahashi M; Kubota-Taniai M; Oshitari T; Yamamoto S
Ophthalmologica; 2012; 228(2):102-9. PubMed ID: 22508168
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.
Engelbert M; Zweifel SA; Freund KB
Retina; 2010 Oct; 30(9):1368-75. PubMed ID: 20517175
[TBL] [Abstract][Full Text] [Related]
14. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
16. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
Tao Y; Jonas JB
Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
[TBL] [Abstract][Full Text] [Related]
18. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.
Finger RP; Charbel Issa P; Schmitz-Valckenberg S; Holz FG; Scholl HN
Retina; 2011; 31(7):1268-78. PubMed ID: 21386758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
